Lantheus Holdings Inc
LNTH
View Detailed Chart
54.900USD
-0.600-1.08%
Close 08/29, 16:00（ET）Quotes delayed by 15 min
3.73BMarket Cap
14.68P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.08%
5 Days
-5.69%
1 Month
-23.58%
6 Months
-41.48%
Year to Date
-38.63%
1 Year
-48.44%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-08-29Key Insights
The company's fundamentals are relatively very healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
13
analysts
Buy
Current Rating
90.154
Target Price
+64.21%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 64.04% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1013.20.
Undervalued
The company’s latest PE is 13.97, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 82.20M shares, decreasing 5.56% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 6.82M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.27.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
Ticker SymbolLNTH
CompanyLantheus Holdings Inc
CEOMr. Brian A. Markison
Websitehttps://www.lantheus.com/
Related Instruments
+1.03%
+0.45%
+0.94%
+0.65%
+0.90%
+0.01%
+0.45%
+0.35%
+0.12%
+0.68%
+0.99%
+0.74%
+0.62%
+4.36%
+1.96%
+0.57%
+0.56%
+0.59%
+0.80%
+4.58%
